CLICK HERE for all tickets
Free for MPS Members, $25 for Non-Members
Agenda:
7:00-7:15 Welcome and Sponsor Introductions
7:15-7:45 David Neubauer, M.D.
7:45-8:15 Christopher Welsh, M.D.
8:15-8:45 Mary Elizabeth Yaden, M.D.
8:45-9:30 Question and Answer Session
Objectives: At the conclusion of the activity participants will be able to:
- Highlight both current and emerging pharmacologic strategies in the treatment of all common sleep disorders, ranging from insomnia to hypersomnia, and even sleep-disordered breathing.
- Describe the DSM-5 diagnosis of Gambling Disorder, screening tools, treatments and services available in Maryland
- Understand ongoing clinical research in the psychedelic medicine, psilocybin, and considerations for future clinical use
Thank you to our supporters:
Accreditation and Designation Statement
In support of improving patient care, this activity has been planned and implemented by American Psychiatric Association (APA) and the Maryland Psychiatric Society. APA is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The APA designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Disclosures
Planning Committee
Jora Hritz has no relevant financial relationships to disclose.
Joshua Chiappelli, M.D. has no relevant financial relationships to disclose.
Paul Nestadt, M.D. has no relevant financial relationships to disclose.
Faculty Disclosures
David Neubauer, M.D. has the following financial relationships to disclose: Advisor: Idorsia Pharmaceuticals; Consultant: Eisai Inc; Advisor: Johnson & Johnson
Mary Elizabeth Yaden, M.D. has no relevant financial relationships to disclose.
Chirstopher Welsh, M.D. has no relevant financial relationships to disclose.